Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial

OBJECTIVE: The present study is a phase I/IIa non-randomized, open-label study to evaluate safety and efficacy of a single, intravenous infusion of autologous, adipose-derived mesenchymal stem cells (adMSCs) over a period of 52 weeks, in patients with active rheumatoid arthritis (RA). METHODS: 15 el...

Descripción completa

Detalles Bibliográficos
Autores principales: Vij, Ridhima, Stebbings, Kevin A., Kim, Hosu, Park, Hyeonggeun, Chang, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896321/
https://www.ncbi.nlm.nih.gov/pubmed/35241141
http://dx.doi.org/10.1186/s13287-022-02763-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896321/
https://www.ncbi.nlm.nih.gov/pubmed/35241141
http://dx.doi.org/10.1186/s13287-022-02763-w

Ejemplares similares